Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
